Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANS03 in Advanced Solid Tumors With ROS1 or NTRK Alterations
NCT06716138Phase 1Recruiting
- Sponsor
- Avistone Biotechnology Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ANS03 in solid tumor, sponsored by Avistone Biotechnology Co., Ltd. Primary endpoints: Incidence of Adverse Events, Incidence of Serious Adverse Events and 3 more. Started Mar 2025; status: recruiting.
02
Drugs
ANS03
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06716138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716138.